GlassScriptPhysician profile
Thomas A Leavens
NPI 1114910460
$7,716.56
in general payments reported to CMS, 2019-2025
49 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,751 · 2020: $1,694 · 2021: $1,041 · 2022: $230.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $854.04 | 2019-2021 | |
| Amgen INC. | $593.64 | 2019-2021 | |
| Ucb, INC. | $527.98 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $424.95 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $423.22 | 2019-2021 | |
| Biogen, INC. | $413.22 | 2019-2021 | |
| Genzyme Corporation | $394.61 | 2019-2021 | |
| Lilly USA, LLC | $331.60 | 2019-2021 | |
| Emd Serono, INC. | $299.83 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $251.84 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $250.25 | 2019-2021 | |
| Genentech USA, INC. | $217.50 | 2019-2022 | |
| Greenwich Biosciences, INC. | $205.89 | 2019-2021 | |
| Sk Life Science, INC. | $202.17 | 2020-2021 | |
| Grifols USA, LLC | $201.26 | 2019-2021 |
Show all 49 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Leavens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.